Merck: Experimental COVID-19 pill combats variants


Merck said results of laboratory studies showed its COVID-19 antiviral drug candidate molnupiravir works against the Delta variant and other known coronavirus variants, and it is most effective when taken in the early part of infection. The experimental drug targets the viral polymerase enzyme necessary for the virus to duplicate itself.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.